Menten AI Stock
Menten AI utilizes machine learning and quantum computing to design proteins for therapeutic and industrial purposes.
Sign up today and learn more about Menten AI Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Menten AI Stock
Menten AI designs new protein drugs and enzymes using quantum computers and machine learning. Proteins are large molecules that can twist into many shapes. Discovering the right shape for a protein to be a drug or a biocatalyst among almost endless possibilities is a major challenge. Menten AI solves this problem by using machine learning and quantum computing to find better starting points for discovery and further development. Quantum computing makes it possible to represent multiple states of the protein simultaneously and efficiently find the best designs. The team created the world’s first peptide designed on a quantum computer and is now working on peptide therapeutics for oncology and neurodegeneration, as well as on enzymes for industrial applications.
Funding History
June 2020 | $4.0M |
---|
Management
Co-Founder and CEO
Hans Melo
Co-Founder and CSO
Tamas Gorbe
Press
linkedin - Apr, 6 2024
Menten AI on LinkedIn: #bioeuropespring #rosettacon #hitdiscovery #drugdiscovery #drugdevelopment…linkedin - Apr, 6 2024
big_bets on LinkedIn: Hans Melo, founder of Menten AI, is co-author of the chapter "The Quantum…linkedin - Apr, 6 2024
How Menten AI uses generative AI for peptide drug design | Menten AI posted on the topicappdevelopermagazine - Dec, 19 2023
Quantum AI tech foresights from GlobalDataglobaldata - Dec, 19 2023
14 Nov, 2023 Quantum AI next big thing in AI evolution ...